Ea2142- Randomized Phase II Study Of Platinum And Etoposide Versus Temozolomide And Capecitabine In Patients With Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Posted Date: May 15, 2019
- Investigator: Olugbenga Olowokure
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal of this study is to assess the progression free survival (PFS) of platinum (cisplatin or carboplatin) and etoposide versus the PFS of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas
Criteria:
To Be Eligible: Patients Must Be 18 Years Of Age Or Older, Must Have Advanced/Unresectable Gastroenteropancreatic Neuroendocrine Carcinoma, No Prior Systemic Treatment For This Malignancy, Life Expentancy Of At Least 3 Months, Nonpregnant And Nonbreastfee
Keywords:
Gastroenteropancreatic, Gastrointestinal, Cancer, Neuroendocrine, Phase Ii
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com